Sarepta Therapeutics, Inc. (SRPT) Insider Ownership

Data spanning the past 90 days through February 07, 2026 reveals that Sarepta Therapeutics's three principal insider shareholders consist of Director Richard Barry (3.11Mn shares), Chief Executive Officer Douglas S Ingram (929.39K shares), Director Michael Andrew Chambers (294.69K shares).

• Sarepta Therapeutics, Inc. (SRPT) exhibits a conventional ownership structure with institutions commanding 89.41% of outstanding shares, insider ownership remaining at 4.94%, and public/other investors holding 5.65%.
• As of February 07, 2026, Sarepta Therapeutics's insider ownership stands at 4.94% of outstanding equity, representing about 4.94Mn shares within the total 99.97Mn shares outstanding.
• Insider ownership levels at Sarepta Therapeutics increased 12.35% across the 90-day window ending February 07, 2026, reflecting insider holdings that growing from 4.40Mn shares to 4.94Mn shares.
• Over the past 90 days through February 07, 2026, Chief Executive Officer Douglas S Ingram demonstrated the strongest insider purchase conviction at Sarepta Therapeutics, adding 539.08K shares to their position.
• As of February 07, 2026, Chief Operating Officer Ian Michael Estepan executed the most significant insider divestiture at Sarepta Therapeutics, disposing of 13.19K shares over the last 90-day period.